TY - JOUR
T1 - Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation
AU - Dalgaard, Frederik
AU - North, Rebecca
AU - Pieper, Karen
AU - Fonarow, Gregg C.
AU - Kowey, Peter R.
AU - Gersh, Bernard J.
AU - Mahaffey, Kenneth W.
AU - Pokorney, Sean
AU - Steinberg, Benjamin A.
AU - Naccarrelli, Gerald
AU - Allen, Larry A.
AU - Reiffel, James A.
AU - Ezekowitz, Michael
AU - Singer, Daniel E.
AU - Chan, Paul S.
AU - Peterson, Eric D.
AU - Piccini, Jonathan P.
N1 - Funding Information:
Dr Dalgaard is funded by The Danish Heart Foundation grant 17-R115-A7443-22062 and Gangstedfonden grant A35136. Rebecca North is funded by T32 National Institutes of Health grant HL079896. Dr Steinberg is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K23HL143156. Dr Chan is supported by grant 1R01HL123980 from the National Heart, Lung, and Blood Institute. The ORBIT-AF registry was sponsored by Janssen Scientific Affairs, LLC, Raritan, NJ.
Funding Information:
B. A. S.: research support from Boston Scientific and Janssen; consulting to Janssen and Merit Medical; speaking for NACCME (funded by Sanofi).
Publisher Copyright:
© 2020
PY - 2020/5
Y1 - 2020/5
N2 - Background: Obstructive sleep apnea (OSA) is a known risk factor for atrial fibrillation (AF). However, it remains unclear whether OSA is independently associated with worse cardiovascular and neurological outcomes in patients with AF. Methods: We used the ORBIT-AF I and ORBIT-AF II to conduct a retrospective cohort study of 22,760 patients with AF with and without OSA. Adjusted multivariable Cox proportional hazards models was used to determine whether OSA was associated with increased risk for major adverse cardiac and neurologic events (MACNEs) (cardiovascular death, myocardial infarction, stroke/transient ischemic attack/non–central nervous system embolism (stroke/SE), and new-onset heart failure], combined and individually. Results: A total of 4,045 (17.8%) patients had OSA at baseline. Median follow-up time was 1.5 (interquartile range: 1-2.2) years, and 1,895 patients experienced a MACNE. OSA patients were younger (median [interquartile range] 68 [61-75] years vs 74 [66-81] years), were more likely male (70.7% vs 55.3%), and had increased body mass index (median 34.6 kg/m2 [29.8-40.2] vs 28.7 kg/m2 [25.2-33.0]). Those with OSA had a higher prevalence of concomitant comorbidities such as diabetes, chronic obstructive pulmonary disease, and heart failure. OSA patients had higher use of antithrombotic therapy. After adjustment, the presence of OSA was significantly associated with MACNE (hazard ratio: 1.16 [95% CI: 1.03-1.31], P =.011). OSA was also an independent risk factor for stroke/SE beyond the CHA2DS2-VASc risk factors (HR: 1.38 [95% CI 1.12-1.70], P =.003) but not cardiovascular death, myocardial infarction, new-onset heart failure, or major bleeding. Conclusions: Among patients with AF, OSA is an independent risk factor for MACNE and, more specifically, stroke/SE.
AB - Background: Obstructive sleep apnea (OSA) is a known risk factor for atrial fibrillation (AF). However, it remains unclear whether OSA is independently associated with worse cardiovascular and neurological outcomes in patients with AF. Methods: We used the ORBIT-AF I and ORBIT-AF II to conduct a retrospective cohort study of 22,760 patients with AF with and without OSA. Adjusted multivariable Cox proportional hazards models was used to determine whether OSA was associated with increased risk for major adverse cardiac and neurologic events (MACNEs) (cardiovascular death, myocardial infarction, stroke/transient ischemic attack/non–central nervous system embolism (stroke/SE), and new-onset heart failure], combined and individually. Results: A total of 4,045 (17.8%) patients had OSA at baseline. Median follow-up time was 1.5 (interquartile range: 1-2.2) years, and 1,895 patients experienced a MACNE. OSA patients were younger (median [interquartile range] 68 [61-75] years vs 74 [66-81] years), were more likely male (70.7% vs 55.3%), and had increased body mass index (median 34.6 kg/m2 [29.8-40.2] vs 28.7 kg/m2 [25.2-33.0]). Those with OSA had a higher prevalence of concomitant comorbidities such as diabetes, chronic obstructive pulmonary disease, and heart failure. OSA patients had higher use of antithrombotic therapy. After adjustment, the presence of OSA was significantly associated with MACNE (hazard ratio: 1.16 [95% CI: 1.03-1.31], P =.011). OSA was also an independent risk factor for stroke/SE beyond the CHA2DS2-VASc risk factors (HR: 1.38 [95% CI 1.12-1.70], P =.003) but not cardiovascular death, myocardial infarction, new-onset heart failure, or major bleeding. Conclusions: Among patients with AF, OSA is an independent risk factor for MACNE and, more specifically, stroke/SE.
UR - http://www.scopus.com/inward/record.url?scp=85081216203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081216203&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2020.01.001
DO - 10.1016/j.ahj.2020.01.001
M3 - Article
C2 - 32179257
AN - SCOPUS:85081216203
SN - 0002-8703
VL - 223
SP - 65
EP - 71
JO - American heart journal
JF - American heart journal
ER -